SIM
DNLI icon

Sandia Investment Management’s Denali Therapeutics DNLI Stock Holding History

Sandia Investment Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,500
Closed -$69.5K – 244
2022
Q4 		$69.5K Buy
+2,500
New +$74.4K 0.01% 182

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sandia Investment Management's DNLI Position: Q1 2023 in Review

Sandia Investment Management sold out of Denali Therapeutics (DNLI) in Q1 2023, closing a stake of 2,500 shares — an estimated $69.5K sold.

Sandia Investment Management first reported a position in DNLI in Q4 2022 and held it in 1 quarter. The position peaked at $69.5K in Q4 2022. 202 funds tracked by Wall St. Rank hold DNLI as of Q1 2023.

  • Sandia Investment Management reported no remaining Denali Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Sandia Investment Management sold 2,500 Denali Therapeutics shares in Q1 2023, an estimated $69.5K.
  • Sandia Investment Management first reported a position in Denali Therapeutics in Q4 2022 and held it in 1 quarter.
  • Sandia Investment Management's Denali Therapeutics position peaked at $69.5K in Q4 2022.
  • 202 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2023.

Based on Sandia Investment Management's 13F filing for Q1 2023, filed 15 May 2023.